Bristol-Myers Squibb Compnay

Bristol-Myers Squibb Holdings Ireland

Julie A Lemm

Min Gao

Nicholas A Meanwell

Makonen Belema

Lawrence B Snyder

Michael H Serrano-Wu

Jin-Hua Sun

Donald R O'Boyle

Donald R O'Boyle, Ii

John F Kadow

Milind Deshpande

Piyasena Hewawasam

Omar D Lopez

Jeffrey Lee Romine

Denis R St Laurent

Van N Nguyen

Fukang Yang

Scott W Martin

Alan Xiangdong Wang

Yuping Qiu

Darren Whitehouse

Yong Tu

Ningning Xu

John E Leet

Xuejie Yang

Samayamunthula Venkata Satya Arun Kumar Gupta

Fiona McPhee

Ramesh Kakarla

Ying-Kai Wang

Pothukanuri Srinivasu

Robert A Fridell

Richard Colonno

Susan E Chaniewski

Amy K Sheaffer

Ponugupati Suresh Kumar

Indasi Gopi Kumar

Stacey A Voss

Peter Nower

Karen Rigat

Chunfu Wang

Fiona Mcphee

Donald R O'BOYLE Ii

Ramesh Kakaria

Donald R Ii O'BOYLE

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Hepatitis C virus inhibitors

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising such compounds, and methods for treating Hepatitis C using such combinations.

Combinations of hepatitis C virus inhibitors

Compounds having the structure of formula I are described. The compounds can inhibit hepatitis C virus (HCV) replication, and in particular can inhibit the function of the HCV NS5A protein.

Inhibitors of HCV replication

The present invention includes an assay useful for identifying inhibitors of Hepatitis C virus (HCV) activity. Particularly, the present invention is directed to a dual HCV assay useful for high throughput screening that quantifies both the amount of HCV RNA replication inhibitory activity associated with a test compound and the amount of cytotoxicity associated with that test compound. The present invention also includes compounds discovered using this assay, compositions containing such compounds and methods of treating Hepatitis C by the administration of such compounds. The present invention also includes reporter assays using enzymes associated with HCV RNA replication, as well as a cell line having ATTC Accession No. PTA-4583.

Hepatitis C virus assays

Compounds having the structure of formula I are described  wherein R, R', R, R, and Rare as defined in the specification. The compounds can inhibit hepatitis C virus (HCV) replication, and in particular the function of the HCV NS5A protein.

Iminothiazolidinones as inhibitors of HCV replication

Growing community of inventors

Durham, CT, United States of America

Julie A Lemm